Amoxicillin/Vonoprazan Shortage: What Providers and Prescribers Need to Know in 2026

Amoxicillin/Vonoprazan (Voquezna Dual Pak) represents a meaningful advancement in H. pylori eradication therapy — a first-in-class PCAB combined with amoxicillin in a convenient 14-day co-package. Yet prescribers are increasingly encountering patient callbacks reporting that their pharmacy doesn't have it. This briefing provides clinicians with the current availability landscape, an evidence-based prescribing framework, and practical tools for ensuring patients get timely treatment.

Current Availability Status (2026)

Voquezna Dual Pak is not listed on the FDA Drug Shortage Database as of 2026. Phathom Pharmaceuticals has not reported manufacturing or supply chain disruptions. The availability challenges your patients are experiencing are downstream of pharmacy stocking patterns, not an upstream manufacturing issue.

Root causes of limited pharmacy availability:

• Recent market entry: Commercial availability began December 2023 following a 19-month post-approval delay related to nitrosamine impurity review.
• Brand-only status: No generic vonoprazan exists in the U.S. Pharmacies prioritize inventory space for high-volume generics.
• Prior authorization friction: Many commercial and Part D plans place Voquezna Dual Pak at Tier 3–4 with PA requirements, which discourages pharmacies from stocking proactively.
• Specialty adoption curve: Gastroenterologists were early adopters; primary care prescribing is still ramping up in many markets, keeping per-pharmacy volume low.

2024 ACG Guideline Updates Relevant to Prescribing Decisions

The 2024 American College of Gastroenterology (ACG) guidelines represent a major shift in H. pylori treatment strategy. Key updates include:

• Optimized bismuth quadruple therapy (BQT) is the preferred first-line regimen for treatment-naive patients when susceptibility is unknown.
• PPI-based clarithromycin triple therapy is no longer recommended as an empiric first-line option, given U.S. clarithromycin resistance rates of approximately 32%.
• Vonoprazan dual therapy (amoxicillin + vonoprazan, i.e., Voquezna Dual Pak) is listed as a suggested first-line alternative for treatment-naive patients, based on the PHALCON-HP trial showing non-inferiority in clarithromycin-susceptible strains and superiority in clarithromycin-resistant strains.
• Rifabutin triple therapy (Talicia) is also listed as an empiric first-line alternative with very low resistance rates (< 3% for rifabutin).

Prescribing Strategy When Voquezna Dual Pak Is Unavailable

When a patient cannot access Voquezna Dual Pak in a timely manner, the following evidence-based alternatives are appropriate:

• Bismuth Quadruple Therapy (BQT): PPI + bismuth subsalicylate 524 mg QID + metronidazole 500 mg TID–QID + tetracycline 500 mg QID for 14 days. Eradication 85–90%. Generic cost: $30–$80. Most accessible option.
• Rifabutin Triple Therapy (Talicia): Omeprazole/amoxicillin/rifabutin TID for 14 days. Best for multidrug-resistant or previously treated patients. Cost $500–$800 brand.
• Voquezna Triple Pak: Vonoprazan + amoxicillin + clarithromycin BID for 14 days. Suggested when clarithromycin susceptibility can be documented; may have similar access challenges as Dual Pak.

Insurance and Prior Authorization Considerations

Most commercial and Medicare Part D plans place Voquezna Dual Pak at Tier 3 or higher, often requiring prior authorization. PA criteria typically require documentation of H. pylori-positive testing and, in some plans, evidence of PPI intolerance or failure of a first-line regimen.

For patients with commercial insurance who have been approved, Phathom Pharmaceuticals offers a Voquezna Savings Card that reduces patient out-of-pocket cost to as little as $25 per fill (maximum 2 fills). This offer expires 12/31/2026 and is not available for Medicare or Medicaid patients.

Practical Recommendations for Your Practice

• Identify preferred pharmacies in your market. Identify 2–3 local pharmacies (typically large chains or hospital outpatient) that stock Voquezna Dual Pak and direct patients there.
• Pre-submit PAs when appropriate. If you're in a market where commercial plans commonly PA vonoprazan, initiate the PA at the time of diagnosis to minimize delay.
• Counsel patients to check mail-order. Many insurers now offer mail-order delivery of specialty drugs; this bypasses local stocking issues but adds a few days.
• Use medfinder for real-time pharmacy search.[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop medfinder.com/providers offers provider-facing tools to help identify which local pharmacies have Voquezna Dual Pak in stock, saving time for your care team.
• Set a clear "no-fill" contingency. At the time of prescribing, inform patients: "If you can't find this at a pharmacy within 48 hours, call our office and we'll switch you to bismuth quadruple therapy." This prevents delays in treatment.

The Bottom Line for Clinicians

Voquezna Dual Pak is an effective, guideline-supported regimen that improves on PPI-based H. pylori therapy. Its current availability limitations are structural and expected to improve with broader adoption. In the meantime, establishing clear prescribing protocols — including pharmacy identification, PA pre-submission, and a defined fallback to BQT — will protect your patients from treatment delays. Visit medfinder.com/providers for pharmacy availability tools.